211 related articles for article (PubMed ID: 24157985)
21. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.
Massaro AM; Lenz KL
Ann Pharmacother; 2005 Jan; 39(1):77-85. PubMed ID: 15562136
[TBL] [Abstract][Full Text] [Related]
22. [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer].
Lorenzen S; Spörl S; Lordick F
Z Gastroenterol; 2014 Aug; 52(8):821-30. PubMed ID: 25111723
[TBL] [Abstract][Full Text] [Related]
23. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.
Abe M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hirashima Y
Biomed Res Int; 2015; 2015():956785. PubMed ID: 26425564
[TBL] [Abstract][Full Text] [Related]
25. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Aksoylar S; Akman SA; Ozgenç F; Kansoy S
Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
[TBL] [Abstract][Full Text] [Related]
26. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
28. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.
Langley-DeGroot M; Ma JD; Hirst J; Roeland EJ
J Pain Palliat Care Pharmacother; 2015 Jun; 29(2):148-52. PubMed ID: 26095486
[TBL] [Abstract][Full Text] [Related]
30. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
31. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.
Srivastava M; Brito-Dellan N; Davis MP; Leach M; Lagman R
J Pain Symptom Manage; 2003 Jun; 25(6):578-82. PubMed ID: 12782438
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of drug-induced nausea and vomiting].
Herrstedt J; Dombernowsky P
Ugeskr Laeger; 1994 Jan; 156(4):453-60. PubMed ID: 8140660
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
Navari RM; Gray SE; Kerr AC
J Support Oncol; 2011; 9(5):188-95. PubMed ID: 22024310
[TBL] [Abstract][Full Text] [Related]
36. Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.
Maeda A; Yoshida H; Inoue H; Ejiri M; Yamaguchi S; Kushihara H; Yamamoto Y; Ando Y; Sato Y; Tashiro Y; Hasegawa A; Takahara Y; Mizutani M; Oze I; Shimizu J
Ann Palliat Med; 2021 Mar; 10(3):2699-2708. PubMed ID: 33615803
[TBL] [Abstract][Full Text] [Related]
37. [The prevention and treatment of nausea and vomiting during cancer chemotherapy].
Shparyk IaV; Bilyns'kyĭ BT; Koval'chuk IV; Petriv RM; Kachmar TB; Ohorchak MA
Lik Sprava; 1997; (4):148-52. PubMed ID: 9471361
[TBL] [Abstract][Full Text] [Related]
38. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
Goodman M
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
[TBL] [Abstract][Full Text] [Related]
39. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.
Jordan K; Roila F; Molassiotis A; Maranzano E; Clark-Snow RA; Feyer P;
Support Care Cancer; 2011 Mar; 19 Suppl 1():S37-42. PubMed ID: 20824481
[TBL] [Abstract][Full Text] [Related]
40. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
